


1151

1152



1153

1154 **Figure S1:** Anti-apoptosis mediated by ADSC-NVs *in vitro*. (A) Viability of
 1155 ADSC-NVs or ADSC-EVs treated HUVECs was measured by Annexin-V-
 1156 FITC/PI staining. We defined Annexin V+/PI- as early apoptotic stage, Annexin
 1157 V+/PI+ as apoptotic cells, and Annexin V-/PI+ as dead cells. Total apoptotic rate
 1158 was the sum of early apoptotic rate and apoptotic rate. (B, C) mRNA
 1159 expressions of B-cell lymphoma-2 (Bcl-2) (B) and BCL2-associated X (Bax) (C)
 1160 in HUVECs treated with ADSC-NVs or ADSC-EVs were analyzed using qRT-
 1161 PCR (n = 3 per group). (D) Protein levels of Bcl-2 and Bax in HUVECs after
 1162 ADSC-NVs or ADSC-EVs stimulation. *p < 0.05, **p < 0.01, ***p < 0.001,
 1163 ****p < 0.0001.